Patent intelligence · US
US 7902167
Compounds and methods for down-regulating Wrap53 protein by RNA interference
Compounds and methods for down-regulating Wrap53 protein by RNA interference
Patent details — US 7902167
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 8, 2011
- Expiration
- Mar 3, 2031
- Applicant
- APREA AB
- Claims
- 20
- CPC classes
- A61K, A61K31/7105, A61P, A61P35/00
Quick answer
US 7902167 (Compounds and methods for down-regulating Wrap53 protein by RNA interference) is held by APREA AB. Status: granted. Granted Mar 8, 2011. Expires Mar 3, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APREA AB
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/7105, A61P, A61P35/00, A61P35/04
More from APREA AB
Related pharmaceutical patents in our USPTO index.
-
US 9061016
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
granted -
US 7759361
Azabicyclooctan-3-one derivatives and use thereof
granted -
US 7659278
Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
granted -
US 7348330
1-azabicyclo [2,2,2] octan-3-one derivatives
granted -
US 6921765
1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
expired
Related coverage
Medicare price rule could hit Keytruda and Opdivo subcutaneous launches
CMS is proposing a Medicare drug price rule that could shape the outlook for subcutaneous Keytruda and Opdivo. The products are expected to be eligible for selection in the 2027 negotiation round for IPAY 2029.
FDA approves belzutifan plus pembrolizumab for adjuvant RCC
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. The catalyst is based on phase 3 LITESPARK-022 data and adds another regulatory milestone for belzutifan.
FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC
The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma. The move extends Merck’s renal cancer catalyst path after evidence showed improved disease-free survival versus pembrolizumab alone.
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.
Frequently asked questions
What is US patent 7902167?
US 7902167 (Compounds and methods for down-regulating Wrap53 protein by RNA interference) is held by APREA AB. Status: granted. Granted Mar 8, 2011. Expires Mar 3, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7902167?
APREA AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 7902167 expire?
Our index shows an expiration date of Mar 3, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.